The European Medicines Agency's Paediatric Committee (PDCO) has scheduled a meeting from 21 to 24 July 2026, according to the agenda published on 21 July 2026. The meeting will address paediatric investigation plans and other regulatory matters related to medicines for children.
No prior coverage of PDCO activities in the last 180 days is available. The meeting is part of the committee's routine work to evaluate and agree on paediatric investigation plans, which are required for the development of medicines for children. The agenda typically includes discussions on waivers, deferrals, and compliance with paediatric obligations under EU regulation.
The PDCO is responsible for assessing the content of paediatric investigation plans and advising the EMA's Committee for Medicinal Products for Human Use on paediatric matters. The outcome of the meeting may influence the approval and labelling of medicines for paediatric use across the EU.
Stakeholders impacted include pharmaceutical companies developing paediatric medicines, who must align with PDCO decisions; healthcare professionals treating children, who rely on approved paediatric indications; and paediatric patients and their families, who benefit from improved access to age-appropriate medicines. The meeting's decisions may impose additional clinical trial requirements or grant waivers, affecting development timelines and costs for industry.
No further details on specific agenda items or decisions are available from the published title alone.